Ad
Skip to content
Subscribe Now
AI in practice
Copy the url to clipboard Share this article Go to comment section

Isomorphic Labs prepares for its first human trials with drugs designed by AlphaFold

Matthias Bastian
Matthias Bastian View the LinkedIn Profile of Matthias Bastian
Jul 7, 2025

Isomorphic Labs, a Deepmind spin-off focused on drug discovery, is getting ready for its first clinical trials with drugs designed using AlphaFold-based AI models.

"We're staffing up now. We're getting very close," said Colin Murdoch, President of Isomorphic Labs and Chief Business Officer at Deepmind, in an interview with Fortune.

The company wants to overhaul the traditionally slow and expensive process of drug development, with anti-cancer drugs already in the pipeline. Isomorphic Labs has signed agreements with Eli Lilly and Novartis, and in 2025 closed a USD 600 million investment round led by Thrive Capital.

Looking ahead, Isomorphic Labs has even bigger ambitions for AI in medicine. "One day we hope to be able to say— well, here's a disease, and then click a button and out pops the design for a drug to address that disease," Murdoch said.

AI News Without the Hype – Curated by Humans

Subscribe to THE DECODER for ad-free reading, a weekly AI newsletter, our exclusive "AI Radar" frontier report six times a year, full archive access, and access to our comment section.

Read on for the full picture.
Subscribe for hype-free coverage.

  • Access to all THE DECODER articles.
  • Read without distractions – no Google ads.
  • Access to comments and community discussions.
  • Weekly AI newsletter.
  • 6 times a year: “AI Radar” – deep dives on key AI topics.
  • Up to 25 % off on KI Pro online events.
  • Access to our full ten-year archive.
  • Get the latest AI news from The Decoder.
Subscribe to The Decoder